Evidence map›Paper›PMID 34554850›Full record

ArticleJournal of clinical oncology : official journal of the American Society of Clinical Oncology2021

Are Platinum Drugs Ineffective for Triple-Negative Breast Cancer With Residual Invasive Disease After Neoadjuvant Chemotherapy?

Yumiko Shimanuki, Akihiko Shimomura, Kenichi Yoshimura, Hiroyuki Terakado, Chikako Shimizu

Abstract readLetterComment
PubMed Publisher
In one paragraph

Article in Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed.

  1. Review
  2. Reply to T. Shimoi et al and Y. Shimanuki et al.Journal of clinical oncology : official journal of the American Society of Clinical Oncology · 2021
    Article
  3. Review
4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

5 authors.

Yumiko ShimanukiYumiko Shimanuki, RPh, Department of Pharmacy, National Center for Global Health and Medicine, Tokyo, Japan; Akihiko Shimomura, MD, PhD, Department of Breast and Medical Oncology, National Center for Global Health and Medicine, Tokyo, Japan; Kenichi Yoshimura, PhD, Medical Center for Translational and Clinical Research, Hiroshima University Hospital, Hiroshima, Japan; Hiroyuki Terakado, RPh, Department of Pharmacy, National Center for Global Health and Medicine, Tokyo, Japan; and Chikako Shimizu, MD, PhD, Department of Breast and Medical Oncology, National Center for Global Health and Medicine, Tokyo, Japan.
Akihiko ShimomuraYumiko Shimanuki, RPh, Department of Pharmacy, National Center for Global Health and Medicine, Tokyo, Japan; Akihiko Shimomura, MD, PhD, Department of Breast and Medical Oncology, National Center for Global Health and Medicine, Tokyo, Japan; Kenichi Yoshimura, PhD, Medical Center for Translational and Clinical Research, Hiroshima University Hospital, Hiroshima, Japan; Hiroyuki Terakado, RPh, Department of Pharmacy, National Center for Global Health and Medicine, Tokyo, Japan; and Chikako Shimizu, MD, PhD, Department of Breast and Medical Oncology, National Center for Global Health and Medicine, Tokyo, Japan.ORCID 0000-0002-2557-8170
Kenichi YoshimuraYumiko Shimanuki, RPh, Department of Pharmacy, National Center for Global Health and Medicine, Tokyo, Japan; Akihiko Shimomura, MD, PhD, Department of Breast and Medical Oncology, National Center for Global Health and Medicine, Tokyo, Japan; Kenichi Yoshimura, PhD, Medical Center for Translational and Clinical Research, Hiroshima University Hospital, Hiroshima, Japan; Hiroyuki Terakado, RPh, Department of Pharmacy, National Center for Global Health and Medicine, Tokyo, Japan; and Chikako Shimizu, MD, PhD, Department of Breast and Medical Oncology, National Center for Global Health and Medicine, Tokyo, Japan.
Hiroyuki TerakadoYumiko Shimanuki, RPh, Department of Pharmacy, National Center for Global Health and Medicine, Tokyo, Japan; Akihiko Shimomura, MD, PhD, Department of Breast and Medical Oncology, National Center for Global Health and Medicine, Tokyo, Japan; Kenichi Yoshimura, PhD, Medical Center for Translational and Clinical Research, Hiroshima University Hospital, Hiroshima, Japan; Hiroyuki Terakado, RPh, Department of Pharmacy, National Center for Global Health and Medicine, Tokyo, Japan; and Chikako Shimizu, MD, PhD, Department of Breast and Medical Oncology, National Center for Global Health and Medicine, Tokyo, Japan.
Chikako ShimizuYumiko Shimanuki, RPh, Department of Pharmacy, National Center for Global Health and Medicine, Tokyo, Japan; Akihiko Shimomura, MD, PhD, Department of Breast and Medical Oncology, National Center for Global Health and Medicine, Tokyo, Japan; Kenichi Yoshimura, PhD, Medical Center for Translational and Clinical Research, Hiroshima University Hospital, Hiroshima, Japan; Hiroyuki Terakado, RPh, Department of Pharmacy, National Center for Global Health and Medicine, Tokyo, Japan; and Chikako Shimizu, MD, PhD, Department of Breast and Medical Oncology, National Center for Global Health and Medicine, Tokyo, Japan.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

PubMed holds no abstract for this paper.

Indexed as

Breast NeoplasmsPharmaceutical PreparationsTriple Negative Breast NeoplasmsAntineoplastic Combined Chemotherapy ProtocolsFemaleHumansNeoadjuvant TherapyPlatinumPharmaceutical PreparationsPlatinum

Identifiers

PMID34554850

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.